Two neonatal cholestasis patients with mutations in the SRD5B1 (AKR1D1) gene: Diagnosis and bile acid profiles during chenodeoxycholic acid treatment

Yoshitaka Seki, Tatsuki Mizuochi, Akihiko Kimura, Tomoyuki Takahashi, Akira Ohtake, Shin Ichi Hayashi, Toshiya Morimura, Yasuharu Ohno, Takayuki Hoshina, Kenji Ihara, Hajime Takei, Hiroshi Nittono, Takao Kurosawa, Keiko Homma, Tomonobu Hasegawa, Toyojiro Matsuishi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and aims: In two Japanese infants with neonatal cholestasis, 3-oxo-Δ4-steroid 5β-reductase deficiency was diagnosed based on mutations of the SRD5B1 gene. Unusual bile acids such as elevated 3-oxo-Δ4 bile acids were detected in their serum and urine by gas chromatography-mass spectrometry. We studied effects of oral chenodeoxycholic acid treatment. Patients and methods: SRD5B1 gene analysis used peripheral lymphocyte genomic DNA. Diagnosis and treatment of these two patients were investigated retrospectively and prospectively investigated. Results: With respect to SRD5B1, one patient was heterozygous (R266Q, a novel mutation) while the other was a compound heterozygote (G223E/R261C). Chenodeoxycholic acid treatment was effective in improving liver function and decreasing unusual bile acids such as 7α-hydroxy- and 7α,12α- dihydroxy-3-oxo-4-cholen-24-oic acids in serum and urine. Conclusion: Primary bile acid treatment using chenodeoxycholic acid was effective for these patients treated in early infancy before the late stage of chronic cholestatic liver dysfunction.

Original languageEnglish
Pages (from-to)565-573
Number of pages9
JournalJournal of Inherited Metabolic Disease
Volume36
Issue number3
DOIs
Publication statusPublished - 2013 May

Fingerprint

Chenodeoxycholic Acid
Cholestasis
Bile Acids and Salts
Mutation
Genes
Urine
Therapeutics
Heterozygote
Serum
Gas Chromatography-Mass Spectrometry
Liver Diseases
Oxidoreductases
Steroids
Lymphocytes
Acids
Liver
DNA

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Two neonatal cholestasis patients with mutations in the SRD5B1 (AKR1D1) gene : Diagnosis and bile acid profiles during chenodeoxycholic acid treatment. / Seki, Yoshitaka; Mizuochi, Tatsuki; Kimura, Akihiko; Takahashi, Tomoyuki; Ohtake, Akira; Hayashi, Shin Ichi; Morimura, Toshiya; Ohno, Yasuharu; Hoshina, Takayuki; Ihara, Kenji; Takei, Hajime; Nittono, Hiroshi; Kurosawa, Takao; Homma, Keiko; Hasegawa, Tomonobu; Matsuishi, Toyojiro.

In: Journal of Inherited Metabolic Disease, Vol. 36, No. 3, 05.2013, p. 565-573.

Research output: Contribution to journalArticle

Seki, Y, Mizuochi, T, Kimura, A, Takahashi, T, Ohtake, A, Hayashi, SI, Morimura, T, Ohno, Y, Hoshina, T, Ihara, K, Takei, H, Nittono, H, Kurosawa, T, Homma, K, Hasegawa, T & Matsuishi, T 2013, 'Two neonatal cholestasis patients with mutations in the SRD5B1 (AKR1D1) gene: Diagnosis and bile acid profiles during chenodeoxycholic acid treatment', Journal of Inherited Metabolic Disease, vol. 36, no. 3, pp. 565-573. https://doi.org/10.1007/s10545-012-9526-6
Seki, Yoshitaka ; Mizuochi, Tatsuki ; Kimura, Akihiko ; Takahashi, Tomoyuki ; Ohtake, Akira ; Hayashi, Shin Ichi ; Morimura, Toshiya ; Ohno, Yasuharu ; Hoshina, Takayuki ; Ihara, Kenji ; Takei, Hajime ; Nittono, Hiroshi ; Kurosawa, Takao ; Homma, Keiko ; Hasegawa, Tomonobu ; Matsuishi, Toyojiro. / Two neonatal cholestasis patients with mutations in the SRD5B1 (AKR1D1) gene : Diagnosis and bile acid profiles during chenodeoxycholic acid treatment. In: Journal of Inherited Metabolic Disease. 2013 ; Vol. 36, No. 3. pp. 565-573.
@article{ecb2c0b425514259a57013d833783cf9,
title = "Two neonatal cholestasis patients with mutations in the SRD5B1 (AKR1D1) gene: Diagnosis and bile acid profiles during chenodeoxycholic acid treatment",
abstract = "Background and aims: In two Japanese infants with neonatal cholestasis, 3-oxo-Δ4-steroid 5β-reductase deficiency was diagnosed based on mutations of the SRD5B1 gene. Unusual bile acids such as elevated 3-oxo-Δ4 bile acids were detected in their serum and urine by gas chromatography-mass spectrometry. We studied effects of oral chenodeoxycholic acid treatment. Patients and methods: SRD5B1 gene analysis used peripheral lymphocyte genomic DNA. Diagnosis and treatment of these two patients were investigated retrospectively and prospectively investigated. Results: With respect to SRD5B1, one patient was heterozygous (R266Q, a novel mutation) while the other was a compound heterozygote (G223E/R261C). Chenodeoxycholic acid treatment was effective in improving liver function and decreasing unusual bile acids such as 7α-hydroxy- and 7α,12α- dihydroxy-3-oxo-4-cholen-24-oic acids in serum and urine. Conclusion: Primary bile acid treatment using chenodeoxycholic acid was effective for these patients treated in early infancy before the late stage of chronic cholestatic liver dysfunction.",
author = "Yoshitaka Seki and Tatsuki Mizuochi and Akihiko Kimura and Tomoyuki Takahashi and Akira Ohtake and Hayashi, {Shin Ichi} and Toshiya Morimura and Yasuharu Ohno and Takayuki Hoshina and Kenji Ihara and Hajime Takei and Hiroshi Nittono and Takao Kurosawa and Keiko Homma and Tomonobu Hasegawa and Toyojiro Matsuishi",
year = "2013",
month = "5",
doi = "10.1007/s10545-012-9526-6",
language = "English",
volume = "36",
pages = "565--573",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Two neonatal cholestasis patients with mutations in the SRD5B1 (AKR1D1) gene

T2 - Diagnosis and bile acid profiles during chenodeoxycholic acid treatment

AU - Seki, Yoshitaka

AU - Mizuochi, Tatsuki

AU - Kimura, Akihiko

AU - Takahashi, Tomoyuki

AU - Ohtake, Akira

AU - Hayashi, Shin Ichi

AU - Morimura, Toshiya

AU - Ohno, Yasuharu

AU - Hoshina, Takayuki

AU - Ihara, Kenji

AU - Takei, Hajime

AU - Nittono, Hiroshi

AU - Kurosawa, Takao

AU - Homma, Keiko

AU - Hasegawa, Tomonobu

AU - Matsuishi, Toyojiro

PY - 2013/5

Y1 - 2013/5

N2 - Background and aims: In two Japanese infants with neonatal cholestasis, 3-oxo-Δ4-steroid 5β-reductase deficiency was diagnosed based on mutations of the SRD5B1 gene. Unusual bile acids such as elevated 3-oxo-Δ4 bile acids were detected in their serum and urine by gas chromatography-mass spectrometry. We studied effects of oral chenodeoxycholic acid treatment. Patients and methods: SRD5B1 gene analysis used peripheral lymphocyte genomic DNA. Diagnosis and treatment of these two patients were investigated retrospectively and prospectively investigated. Results: With respect to SRD5B1, one patient was heterozygous (R266Q, a novel mutation) while the other was a compound heterozygote (G223E/R261C). Chenodeoxycholic acid treatment was effective in improving liver function and decreasing unusual bile acids such as 7α-hydroxy- and 7α,12α- dihydroxy-3-oxo-4-cholen-24-oic acids in serum and urine. Conclusion: Primary bile acid treatment using chenodeoxycholic acid was effective for these patients treated in early infancy before the late stage of chronic cholestatic liver dysfunction.

AB - Background and aims: In two Japanese infants with neonatal cholestasis, 3-oxo-Δ4-steroid 5β-reductase deficiency was diagnosed based on mutations of the SRD5B1 gene. Unusual bile acids such as elevated 3-oxo-Δ4 bile acids were detected in their serum and urine by gas chromatography-mass spectrometry. We studied effects of oral chenodeoxycholic acid treatment. Patients and methods: SRD5B1 gene analysis used peripheral lymphocyte genomic DNA. Diagnosis and treatment of these two patients were investigated retrospectively and prospectively investigated. Results: With respect to SRD5B1, one patient was heterozygous (R266Q, a novel mutation) while the other was a compound heterozygote (G223E/R261C). Chenodeoxycholic acid treatment was effective in improving liver function and decreasing unusual bile acids such as 7α-hydroxy- and 7α,12α- dihydroxy-3-oxo-4-cholen-24-oic acids in serum and urine. Conclusion: Primary bile acid treatment using chenodeoxycholic acid was effective for these patients treated in early infancy before the late stage of chronic cholestatic liver dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=84877766318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877766318&partnerID=8YFLogxK

U2 - 10.1007/s10545-012-9526-6

DO - 10.1007/s10545-012-9526-6

M3 - Article

C2 - 23160874

AN - SCOPUS:84877766318

VL - 36

SP - 565

EP - 573

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 3

ER -